Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study

Lung Cancer

Volumn 34, Issue SUPPL. 4, 2001, Pages 31-35

  Valerio, Maria Rosaria ^a   Russo, Antonio ^a   Latteri, Mario Adelfio ^a   Modica, Giuseppe ^a   Gulotta, Gaspare ^a   Armata, Maria Gabriella ^a   Bajardi, Eugenia ^a   Cicero, Giuseppe ^a   Pantuso, Giovanni ^a   Grassi, Nello ^a   Agosta, Giacoma ^a   Gebbia, Nicola ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Docetaxel; Non small cell lung cancer; Overall response rate

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANISETRON;

ADULT; AGED; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONJUNCTIVITIS; DRUG EFFICACY; EVALUATION; FEMALE; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0035198559     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00402-0     Document Type: Conference Paper

References (45)

1. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
2. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
3. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non small cell lung cancer
4. Symptom relief with MVP (mitomycin C, vinblastina and cisplatin) chemotherapy in advanced non-small-cell lung cancer
5. 2 docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
6. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy
7. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study
8. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
9. Where to go with new expensive treatment in NSCLC
10. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
11. Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer (NSCLC)
12. Second-line with vinorelbine in the weekly monochemotherapy for treatment of advanced non-small cell lung cancer
13. Failure of vinorelbine to produce responses in pre-treated non-small cell lung cancer patients
14. Gemcitabine as second-line treatment for relapsing or refractory non-small cell lung cancer: a phase II trial
15. Second line gemcitabine (G) therapy in non-small cell lung cancer (NSCLC) stage IIIB and IV
16. Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 trial
17. Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC)
18. Second-line chemotherapy for resistant metastatic non-small cell lung cancer: the role of Taxol
19. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotherapy
20. Second-line chemotherapy with 96 hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial
21. A phase II stadi of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 co-operative study group
22. An early phase II study of CPT-11 for primary lung cancer
23. Single agents in the second-line treatment of non-small cell lung cancer
24. Phase II trials of taxotere in patients with non-small cell lung cancer
25. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer
26. Single-agent docetaxel in patients with refractory non-small cell lung cancer
27. Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival
28. Phase II study of docetaxel (Taxotere) in first and second line NSCLC
29. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial
30. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
31. Randomized phase III trial of docetaxel versus vinorelbine or iphosphamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
32. Phase I study of weekly docetaxel (Taxotere) in heavily pretreated breast cancer patients
33. Activity of weekly taxotere (TXT) in patients with metastatic breast cancer
34. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
35. The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent
36. Reporting results of cancer treatment
37. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
38. The EORTC QLQ-LC13: a modular supplement to the EORTC core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials
39. Cancer of the lung
40. Chemotherapy for unresectable non-small cell lung cancer
41. Chemotherapy of lung cancer
42. Phase II study of gemcitabine (GEM) and gemcitabine+vinorelbine (GemVin) in advanced NSCLC elderly patients within the phase III Miles (Multicenter Italian Lung Cancer in the Elderly Study) randomized trial
43. Early phase II of docetaxel in second line of advanced non small cell lung cancer (NSCLC): preliminary results
44. Weekly docetaxel as second line therapy of advanced non small cell lung cancer (NSCLC): a preliminary feasibility report
45. Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC)